Fig. 3From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in IranIncremental cost-effectiveness scatter plot of LDX vs. MPH in patients under 18 years old in IranBack to article page